Humacyte’s (HUMA) “Buy” Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a report issued on Tuesday,Benzinga reports. BTIG Research currently has a $2.00 price target on the stock.

Several other research firms have also recently issued reports on HUMA. Benchmark decreased their price objective on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating on the stock in a report on Thursday, August 13th. HC Wainwright reiterated a “buy” rating on shares of Humacyte in a research report on Friday, October 16th. Williams Trading set a $1.00 target price on Humacyte in a research report on Friday, October 16th. Barclays raised Humacyte to a “hold” rating in a research note on Wednesday, October 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Friday, October 2nd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $4.48.

Humacyte Stock Performance

Shares of NASDAQ HUMA opened at $0.60 on Tuesday. The company has a 50-day simple moving average of $0.49 and a 200-day simple moving average of $0.78. The company has a debt-to-equity ratio of 3.65, a current ratio of 3.34 and a quick ratio of 5.74. The company has a market cap of $165.40 million, a PE ratio of -1.35 and a beta of 2.64. Humacyte has a 12 month low of $0.34 and a 12 month high of $1.52.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Humacyte had a negative net margin of 3,955.05% and a negative return on equity of 612.88%. The firm had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $1.04 million. On average, equities analysts anticipate that Humacyte will post -0.40 earnings per share for the current year.

Institutional Trading of Humacyte

Institutional investors and hedge funds have recently made changes to their positions in the company. Beacon Pointe Advisors LLC purchased a new stake in Humacyte during the second quarter valued at about $28,000. Bank of New York Mellon Corp acquired a new stake in Humacyte during the 2nd quarter worth approximately $44,000. Sei Investments Co. purchased a new position in Humacyte in the first quarter valued at approximately $56,000. Miramontes Capital LLC purchased a new position in Humacyte in the second quarter valued at approximately $85,000. Finally, LaSalle St. Investment Advisors LLC purchased a new position in Humacyte in the second quarter valued at approximately $89,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.